HUTCHMED (China) Limited
NASDAQ:HCMDrug Manufacturers - Specialty & Generic
+$0.16 today
- Market cap
- $2.44B
- Beta
- 0.37
- P/E (TTM)
- 46.2
- EPS (TTM)
- $0.05
Volume 0.04M
Average 0.04M
HCM Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
HUTCHMED (China) LimitedNASDAQ: HCM
Cost of Revenue · Q2 FY2025 · quarter ended Jun 2025
Cost of revenue dips below year-ago levels
Q2 FY2025 cost of revenue of $83.79M fell 7.0% year over year, behind the +53.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +2.7% a year.
Context
- Cost of revenue amounted to 61.3% of revenue in FY2025, up 6.0 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -7.0% toward the trailing-twelve-month pace of +53.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 337.24M USD
- Year-over-year change
- -3.3%
- 4-year CAGR
- +6.9%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 337.24M | -3.3% |
| FY2024 | 2024-12-31 | 348.88M | -9.3% |
| FY2023 | 2023-12-31 | 384.45M | +23.6% |
| FY2022 | 2022-12-31 | 311.1M | +20.5% |
| FY2021 | 2021-12-31 | 258.23M | — |
Cost of Revenue vs competitors
How HCM compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +53.9% is the 4th highest of 8, against a peer median of +32.4%.
- Cost of revenue amounts to 91.1% of revenue for HCM, versus a peer median of 15.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €771.34M EUR | +32.4% | -41.0% | 29.2% | |
| LTM Sep 2026 | $584.36M USD | +63.0% | +84.1% | 43.0% | |
| LTM Jun 2025 | $548.44M USD | +53.9% | +2.7% | 91.1% | |
| LTM Jun 2026 | $429.56M USD | +31.6% | +21.6% | 7.4% | |
| LTM Jun 2026 | $288M USD | — | — | 7.0% | |
| LTM Mar 2026 | $244.96M USD | +232.7% | +29.8% | 108.7% | |
| LTM Jun 2026 | $195.71M USD | +21.7% | +37.2% | 43.5% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥131.73M CNY | +352.9% | +81.6% | 23.6% |
| LTM Jul 2026 | $85.67M USD | +12.8% | +13.1% | 3.5% | |
| LTM Jun 2026 | $7M USD | — | — | 6.0% | |
| LTM Jun 2024 | $0 USD | — | — | 0.0% | |
| Peer median (excluding HCM) | — | +32.4% | +29.8% | 15.5% | |
Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 356.13M | 426.41M | 838M | 630.2M | 549.96M |
| Cost of Revenue | 258.23M | 311.1M | 384.45M | 348.88M | 337.24M |
| Gross Profit | 97.89M | 115.31M | 453.55M | 281.32M | 212.72M |
| Gross Margin | 27.5% | 27.0% | 54.1% | 44.6% | 38.7% |
| Research & Development | 207.45M | 267.59M | 303.06M | 213.37M | 164.15M |
| Selling, General & Admin | 127.13M | 136.11M | 133.18M | 112.91M | 103.3M |
| Operating Expenses | 426.21M | 523M | 436.23M | 321.93M | 267.45M |
| Depreciation & Amortization | 7.19M | 8.66M | 8.21M | 12.34M | 13.34M |
| EBITDA | (207.96M) | (401.11M) | 26.58M | (31.36M) | (41.38M) |
| EBITDA Margin | -58.4% | -94.1% | 3.2% | -5.0% | -7.5% |
| Operating Income | (328.32M) | (409.77M) | 18.38M | (43.71M) | (54.73M) |
| Operating Margin | -92.2% | -96.1% | 2.2% | -6.9% | -10.0% |
| Interest Income | 2.08M | 9.6M | 36.15M | 40.08M | 50.01M |
| Interest Expense | 592K | 652K | 759K | 2.87M | 2.87M |
| Other Income / Expenses | 173.19M | 51.52M | 87.23M | 89.07M | 577.45M |
| Income Before Tax | (155.33M) | (360.24M) | 105.6M | 45.36M | 522.72M |
| Pre-Tax Margin | -43.6% | -84.5% | 12.6% | 7.2% | 95.0% |
| Income Tax Expense | 11.92M | (283K) | 4.51M | 7.19M | 63.78M |
| Net Income | (194.65M) | (360.84M) | 100.78M | 37.73M | 458.12M |
| Net Margin | -54.7% | -84.6% | 12.0% | 6.0% | 83.3% |
| EPS (Basic) | (1.25) | (2.15) | 0.60 | 0.22 | 2.65 |
| EPS (Diluted) | (1.25) | (2.15) | 0.60 | 0.22 | 2.60 |
| Weighted Avg Shares | 158.54M | 169.43M | 169.93M | 171.07M | 171.66M |
| Weighted Avg Shares (Diluted) | 158.54M | 169.43M | 173.84M | 174.57M | 174.58M |
HUTCHMED (China) Limited
NASDAQ:HCM
Intrinsic Alpha fair value
Locked
Current Price
$13.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.